{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:03:57Z","timestamp":1776780237868,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The rate of locoregional recurrence after primary therapy remains at 5\u201315%. Ipsilateral recurrences are most commonly located in the residual breast or chest wall, followed by isolated nodal axillary and supraclavicular recurrences at 1\u20133%. In pre-irradiated patients with inoperable recurrences, re-radio(chemo)therapy can achieve sufficient local tumor control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All inoperable patients with histologically confirmed locoregional recurrence (LRR) who underwent salvage radio(chemo)therapy at the University Medical Center Freiburg were included in this analysis. A\u00a0descriptive assessment of toxicity and oncological endpoints was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A\u00a0total of seven patients were identified. The LRRs were located as follows: two in the chest wall, three parasternal\/sternal, and two supraclavicular. The LRRs occurred after a\u00a0median of 99\u00a0(3\u2013311) months after completion of primary therapy. In four patients, additional osseous involvement (per continuitatem) was diagnosed. The mean dose of prior radiation was 59.7\u00a0Gy. All patients received normofractionated percutaneous radiotherapy, with a\u00a0simultaneous integrated boost with a\u00a0single dose of 1.7\u20132\u202fGy up to a\u00a0total dose of 50.4\u201360\u202fGy, if necessary. Five patients received concomitant chemotherapy with 5\u2011fluorouracil (FU)\/capecitabine. Staging and target volume definition were based on PET-CT or MRI imaging. The median follow-up was 14.8 (1\u201376) months. No high-grade toxicity \u2265\u202f3 was observed. Acute and chronic toxicity grade\u00a01\u20132 was limited to radiodermatitis, fatigue, restriction of arm elevation, and pain. Local tumor control was achieved in all patients. Visceral metastasis occurred in one woman.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Re-irradiation with concurrent chemotherapy in inoperable LRR can achieve reliable local control. Our approach provides additional support for the existing evidence regarding the oncological benefit of combined postoperative radiotherapy and capecitabine in patients with triple-negative breast cancer. Given the established clinical tolerability of re-irradiation protocols, future efforts must prioritize the standardization of concurrent systemic treatments to optimize both safety and therapeutic outcomes in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02528-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:05:30Z","timestamp":1776776730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is re-irradiation combined with chemotherapy an option for inoperable local recurrence of previously irradiated breast cancer? A\u00a0collection of cases"],"prefix":"10.1007","author":[{"given":"Raluca","family":"Stoian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingolf","family":"Juhasz-B\u00f6ss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4052-6632","authenticated-orcid":false,"given":"Tanja","family":"Sprave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"1","key":"2528_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.100640","volume":"6","author":"S Fattahi","year":"2021","unstructured":"Fattahi\u00a0S, Ahmed\u00a0SK, Park\u00a0SS, Petersen\u00a0IA, Shumway\u00a0DA, Stish\u00a0BJ et\u00a0al (2021) Reirradiation for Locoregional Recurrent Breast Cancer. Adv Radiat Oncol 6(1):100640","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"2528_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clon.2017.11.004","volume":"30","author":"O Kaidar-Person","year":"2018","unstructured":"Kaidar-Person\u00a0O, Oldenborg\u00a0S, Poortmans\u00a0P (2018) Re-irradiation and Hyperthermia in Breast Cancer. Clin Oncol (R Coll Radiol) 30(2):73\u201384","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"33","key":"2528_CR3","doi-asserted-by":"publisher","first-page":"35051","DOI":"10.18632\/oncotarget.6036","volume":"6","author":"T Merino","year":"2015","unstructured":"Merino\u00a0T, Tran\u00a0WT, Czarnota\u00a0GJ (2015) Re-irradiation for locally recurrent refractory breast cancer. Oncotarget 6(33):35051\u201335062","journal-title":"Oncotarget"},{"issue":"11","key":"2528_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","volume":"36","author":"IL Wapnir","year":"2018","unstructured":"Wapnir\u00a0IL, Price\u00a0KN, Anderson\u00a0SJ, Robidoux\u00a0A, Martin\u00a0M, Nortier\u00a0JWR et\u00a0al (2018) Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J\u00a0Clin Oncol 36(11):1073\u20131079","journal-title":"J Clin Oncol"},{"issue":"5","key":"2528_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ijrobp.2023.06.075","volume":"117","author":"JM Hannoun-Levi","year":"2023","unstructured":"Hannoun-Levi\u00a0JM, Gal\u00a0J, Polgar\u00a0C, Strnad\u00a0V, Loessl\u00a0K, Polat\u00a0B et\u00a0al (2023) Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis. Int J Radiat Oncol Biol Phys 117(5):1200\u20131210","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2528_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijrobp.2024.11.109","volume":"122","author":"N Kim","year":"2025","unstructured":"Kim\u00a0N, Kim\u00a0SS, Cho\u00a0WK, Park\u00a0W, Chang\u00a0JH, Kim\u00a0YB et\u00a0al (2025) Concurrent Versus Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual Triple-Negative Breast Cancer After Neoadjuvant-Chemotherapy: A Multicenter Comparative Study. Int J Radiat Oncol Biol Phys 122(1):72\u201383","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2528_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00066-016-1010-z","volume":"192","author":"A Auoragh","year":"2016","unstructured":"Auoragh\u00a0A, Strnad\u00a0V, Ott\u00a0OJ, Beckmann\u00a0MW, Fietkau\u00a0R (2016) Re-irradiation of the chest wall for local breast cancer recurrence : Results of salvage brachytherapy with hyperthermia. Strahlenther Onkol 192(9):617\u2013623","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2528_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/curroncol30010088","volume":"30","author":"CH Abeloos","year":"2023","unstructured":"Abeloos\u00a0CH, Purswani\u00a0JM, Galavis\u00a0P, McCarthy\u00a0A, Hitchen\u00a0C, Choi\u00a0JI et\u00a0al (2023) Different Re-Irradiation Techniques after Breast-Conserving Surgery for Recurrent or New Primary Breast Cancer. Curr Oncol 30(1):1151\u20131163","journal-title":"Curr Oncol"},{"issue":"9","key":"2528_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00066-018-1315-1","volume":"194","author":"S Janssen","year":"2018","unstructured":"Janssen\u00a0S, Rades\u00a0D, Meyer\u00a0A, Fahlbusch\u00a0FB, Wildfang\u00a0I, Meier\u00a0A et\u00a0al (2018) Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention. Strahlenther Onkol 194(9):806\u2013814","journal-title":"Strahlenther Onkol"},{"key":"2528_CR10","first-page":"116","volume":"19","author":"P Gabani","year":"2019","unstructured":"Gabani\u00a0P, Patel\u00a0H, Thomas\u00a0MA, Bottani\u00a0B, Goddu\u00a0SM, Straube\u00a0W et\u00a0al (2019) Clinical outcomes and toxicity of proton beam radiation therapy for re-irradiation of locally recurrent breast cancer. Clin Transl Radiat Oncol 19:116\u2013122","journal-title":"Clin Transl Radiat Oncol"},{"key":"2528_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-3-28","volume":"3","author":"F Wurschmidt","year":"2008","unstructured":"Wurschmidt\u00a0F, Dahle\u00a0J, Petersen\u00a0C, Wenzel\u00a0C, Kretschmer\u00a0M, Bastian\u00a0C (2008) Reirradiation of recurrent breast cancer with and without concurrent chemotherapy. Radiat Oncol 3:28","journal-title":"Radiat Oncol"},{"issue":"2","key":"2528_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semradonc.2006.11.006","volume":"17","author":"S Delanian","year":"2007","unstructured":"Delanian\u00a0S, Lefaix\u00a0JL (2007) Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol 17(2):99\u2013107","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"2528_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejrad.2007.10.021","volume":"65","author":"GP Schmidt","year":"2008","unstructured":"Schmidt\u00a0GP, Baur-Melnyk\u00a0A, Haug\u00a0A, Heinemann\u00a0V, Bauerfeind\u00a0I, Reiser\u00a0MF et\u00a0al (2008) Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 65(1):47\u201358","journal-title":"Eur J Radiol"},{"issue":"5","key":"2528_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1600","volume":"8","author":"L Preda","year":"2006","unstructured":"Preda\u00a0L, Villa\u00a0G, Rizzo\u00a0S, Bazzi\u00a0L, Origgi\u00a0D, Cassano\u00a0E et\u00a0al (2006) Magnetic resonance mammography in the evaluation of recurrence at the prior lumpectomy site after conservative surgery and radiotherapy. Breast Cancer Res 8(5):R53","journal-title":"Breast Cancer Res"},{"issue":"9","key":"2528_CR15","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz\u00a0SC, Woll\u00a0JPP, Cardoso\u00a0F, Groheux\u00a0D, Cook\u00a0GJR, Ulaner\u00a0GA et\u00a0al (2024) Joint EANM-SNMMI guideline on the role of 2\u2011[(18)F]FDG PET\/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging 51(9):2706\u20132732","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2528_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejso.2009.11.009","volume":"36","author":"TS Aukema","year":"2010","unstructured":"Aukema\u00a0TS, Rutgers\u00a0EJ, Vogel\u00a0WV, Teertstra\u00a0HJ, Oldenburg\u00a0HS, Vrancken Peeters\u00a0MT et\u00a0al (2010) The role of FDG PET\/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36(4):387\u2013392","journal-title":"Eur J Surg Oncol"},{"issue":"24","key":"2528_CR17","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux\u00a0D, Hindie\u00a0E, Delord\u00a0M, Giacchetti\u00a0S, Hamy\u00a0AS, de Bazelaire\u00a0C et\u00a0al (2012) Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J\u00a0Natl Cancer Inst 104(24):1879\u20131887","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2528_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.clbc.2013.02.003","volume":"13","author":"FP Mghanga","year":"2013","unstructured":"Mghanga\u00a0FP, Lan\u00a0X, Bakari\u00a0KH, Li\u00a0C, Zhang\u00a0Y (2013) Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a\u00a0meta-analysis. Clin Breast Cancer 13(4):271\u2013279","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"2528_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/cncr.24820","volume":"116","author":"AA Martoni","year":"2010","unstructured":"Martoni\u00a0AA, Zamagni\u00a0C, Quercia\u00a0S, Rosati\u00a0M, Cacciari\u00a0N, Bernardi\u00a0A et\u00a0al (2010) Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 116(4):805\u2013813","journal-title":"Cancer"},{"key":"2528_CR20","doi-asserted-by":"crossref","unstructured":"Michalski K, Kemna L, Asberger J, Grosu AL, Meyer PT, Ruf J, et\u00a0al. Gastrin-Releasing Peptide Receptor Antagonist [(68)Ga]RM2 PET\/CT for Staging of Pre-Treated, Metastasized Breast Cancer. Cancers (Basel). 2021;13(23).","DOI":"10.3390\/cancers13236106"},{"key":"2528_CR21","first-page":"461","volume":"9","author":"R Piva","year":"2017","unstructured":"Piva\u00a0R, Ticconi\u00a0F, Ceriani\u00a0V, Scalorbi\u00a0F, Fiz\u00a0F, Capitanio\u00a0S et\u00a0al (2017) Comparative diagnostic accuracy of 18F-FDG PET\/CT for breast cancer recurrence. Breast Cancer (Dove Med Press) 9:461\u2013471","journal-title":"Breast Cancer (Dove Med Press)"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02528-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:05:33Z","timestamp":1776776733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02528-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":21,"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02528-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.\u00a0Stoian, I.\u00a0Juhasz-B\u00f6ss, B.\u00a0Rautenberg, H.\u00a0Sch\u00e4fer, A.-L.\u00a0Grosu, and T.\u00a0Sprave declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional ethical review committee (reference no. 20-1050).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}